drugset

Drugs / BCG-PPD

Follow last change Dec 2025 re-read 3 minutes ago

BCG-PPD

also known as Purified Protein Derivative of BCG

Diagnostic / imaging agent

Investigated by: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · Beijing Kangterike Statistical Technology Co., Ltd. · Shenzhen Third People's Hospital · Neijiang Center for Disease Control and Prevention · Sichuan Center for Disease Control and Prevention · Wuhan Pulmonary Hospital

Trials 3

today NCT06975774 · Ph 1 NCT04538911 · Ph 1 NCT04593771 · Ph 1

202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT06975774	Jul → Dec 2023	tuberculosis	Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT04538911	Jul 2021 → May 2023 overdue	tuberculosis	Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.	Active not recruiting	No outcome recorded
Phase 1	NCT04593771	Oct 2020 → May 2021	tuberculosis	Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.	Completed	No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	BCG-PPD	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04593771 ↗ 2 NCT04538911 ↗ NCT06975774 ↗
Known as	Purified Protein Derivative of BCG	“Purified Protein Derivative of BCG（BCG-PPD）” NCT06975774 ↗
Modality	Diagnostic / imaging agent	“BCG-PPD was used for skin test” NCT04538911 ↗